Mucinous adenocarcinoma of the appendix (MAA) is recognized as a biologically and histologically distinct entity — separate from colorectal cancer and from colonic-type adenocarcinoma of the appendix. This distinction shapes how management is approached.
Mucinous adenocarcinoma of the appendix (MAA) appears to be a biologically and histologically distinct entity from colorectal cancer and from colonic-type adenocarcinoma of the appendix.
Management of MAA is dependent on the histologic type and the extent of disease at presentation.
Mucinous adenocarcinoma of the appendix (MAA) appears to be a biologically and histologically distinct entity from colorectal cancer and from colonic-type adenocarcinoma of the appendix.
Management of MAA is dependent on the histologic type and the extent of disease at presentation, and is outlined in Fig. 3.
For patients not eligible for complete cytoreduction, systemic chemotherapy with regimens utilized for metastatic colorectal cancer is the best initial therapy.
Patients should undergo repeat imaging at intervals of 2 to 3 months to evaluate response to therapy.
DOI: 10.1055/s-0035-1564433
View source ↗